Back to Search
Start Over
Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
- Source :
- Leukemialymphoma. 60(11)
- Publication Year :
- 2019
-
Abstract
- In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts.Clinicaltrials.gov identifier: NCT02453594.
- Subjects :
- Oncology
Adult
Male
Cancer Research
medicine.medical_specialty
Adolescent
Health Status
KEYNOTE-087
Phases of clinical research
Classical Hodgkin lymphoma
Pembrolizumab
patient-reported outcome
Antibodies, Monoclonal, Humanized
03 medical and health sciences
Young Adult
0302 clinical medicine
Overall response rate
Antineoplastic Agents, Immunological
Refractory
immune system diseases
hemic and lymphatic diseases
Internal medicine
medicine
Humans
In patient
Patient Reported Outcome Measures
Aged
Health related quality of life
business.industry
Hematology
Middle Aged
Prognosis
Hodgkin Disease
030220 oncology & carcinogenesis
Quality of Life
health-related quality-of-life
Female
pembrolizumab
business
030215 immunology
Follow-Up Studies
Subjects
Details
- ISSN :
- 10292403
- Volume :
- 60
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Leukemialymphoma
- Accession number :
- edsair.doi.dedup.....805091edf2e681178b76c0296b61aa08